AUTL
Autolus Therapeutics plc
1.90$
-4.6%
vs. previous close
Closing price · As of: Oct 1, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2015 | 2016 | 2017 | 2018 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 0.0% | 39.4% | 59.6% | 4,620.4% | 4,620.4% | 3,625.1% | 7,865.2% | 8,536.9% | 2,215.4% | 386.6% | 1,393.5% | 127.8% | |
| 100.0% | 60.6% | 40.4% | -4,520.4% | -4,520.4% | -3,525.1% | -7,765.2% | 100.0% | 100.0% | 100.0% | -1,293.5% | -27.8% | |
| 2,308.5% | 861.1% | 945.8% | 2,356.9% | 2,356.9% | 3,632.0% | 7,871.0% | 7,354.9% | 1,894.6% | 7,684.4% | 1,562.6% | 170.2% | |
| 6,422.1% | 425.1% | 537.4% | 1,611.5% | 1,611.5% | 1,356.7% | 2,039.2% | 2,114.5% | 515.0% | 2,752.9% | 998.9% | 174.5% | |
| 8,713.8% | 1,286.1% | 1,483.2% | 3,968.4% | 3,968.4% | 4,988.7% | 9,910.2% | 9,414.8% | 2,407.0% | 10,683.1% | 1,092.2% | 344.6% | |
| -8,613.8% | -1,186.1% | -1,383.2% | -5,503.7% | -5,503.7% | -8,513.8% | -17,675.4% | -9,314.8% | -2,307.0% | -10,583.1% | -2,385.6% | -372.4% | |
| 0.0% | 4.0% | 2.2% | 1.2% | 1.2% | 39.5% | 110.1% | 73.3% | 143.8% | 2,654.1% | 91.8% | 48.6% | |
| -8,605.3% | -1,182.1% | -1,381.0% | -3,475.1% | -3,475.1% | -3,737.6% | -9,694.3% | -9,425.2% | -2,398.6% | -12,273.4% | -2,165.4% | -392.8% | |
| -674.2% | -146.6% | -215.8% | -498.6% | -498.6% | 521.3% | -1,408.9% | 3.8% | 4.4% | -1.1% | 15.1% | -11.4% | |
| -7,931.1% | -1,035.5% | -1,165.2% | -2,976.5% | -2,976.5% | -4,258.9% | -8,285.4% | -9,429.1% | -2,403.0% | -12,272.3% | -2,180.5% | -381.4% | |
| -4,749.8% | -1,146.7% | -1,323.6% | -3,368.2% | -4,813.9% | -4,724.8% | -9,479.8% | -8,790.6% | -2,135.0% | -9,232.6% | -2,303.1% | -331.2% |
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.